Population Pharmacokinetic Model to Optimize Cefotaxime Dosing Regimen in Critically Ill Children
During sepsis, optimal plasma antibiotic concentrations are mandatory. Modifications of pharmacokinetic parameters could lead to low drug concentrations and therefore, insufficient therapeutic levels.
The aim of this study was to build a population pharmacokinetic model for cefotaxime and its metabolite desacetylcefotaxime in order to optimize individual dosing regimens for critically ill children.
All children aged < 18 years, weighing more than 2.5 kg, and receiving intermittent cefotaxime infusions were included in this study. Cefotaxime and desacetylcefotaxime were quantified by high-performance liquid chromatography. Pharmacokinetics were described using the non-linear mixed-effect modeling software MONOLIX, and Monte Carlo simulations were used to optimize dosing regimen in order to maintain serum concentrations above the target concentration (defined at 2 mg·L−1) throughout the dosing interval.
We included 49 children with a median (range) postnatal age of 23.7 (0.2–229) months, and median body weight (range) of 10.9 (2.5–68) kg. A one-compartment model with first-order elimination adequately described the data. Median (range) values for cefotaxime clearance, desacetylcefotaxime clearance, and volume of distribution were 0.97 (0.3–7.1) L·h−1, 3.2 (0.6–16.3) L·h−1, and 0.3 (0.2–0.41) L·kg−1, respectively. Body weight and postnatal age were statistically significant covariates. Cefotaxime-calculated residual concentrations were low, and no patient succeeded in attaining the target. Unlike intermittent administration, a dosing regimen of 100 mg·kg−1·day−1 administered by continuous infusion provided a probability of target attainment of 100%, regardless of age and weight.
Standard intermittent cefotaxime dosing regimens in critically ill children are not adequate to reach the target. We showed that, for the same daily dose, continuous infusion was the only administration that enabled the target to be attained, for children over 1 month of age. As continuous administration is achievable in the pediatric intensive care unit, it should be considered for clinical practice.
Trial registration number
Registered at http://www.clinicaltrials.gov, NCT02539407.
The authors thank the PICU team (physicians and nurses) who included the children and realized the samples, making this work possible. They also thank the Pharmacology Laboratory of the Cochin Teaching Hospital, which analyzed the samples. Agathe Béranger is currently receiving a grant from the Agence Régionale de Santé Ile-de-France, for 1 year of research, as a fellow in the EA7323.
Compliance with Ethical Standards
Conflicts of interest
Agathe Béranger, Mehdi Oualha, Saïk Urien, Mathieu Genuini, Sylvain Renolleau, Radia Aboura, Déborah Hirt, Claire Heilbronner, Julie Toubiana, Jean-Marc Tréluyer, and Sihem Benaboud declare no conflicts of interest.
This research study did not receive funds or support from any sources.
Informed consent was obtained from all parents of the children included in the study.
- 2.Amadeo B, Zarb P, Muller A, Drapier N, Vankerckhoven V, Rogues A-M, et al. European Surveillance of Antibiotic Consumption (ESAC) point prevalence survey 2008: paediatric antimicrobial prescribing in 32 hospitals of 21 European countries. J Antimicrob Chemother. 2010;65:2247–52.CrossRefPubMedGoogle Scholar
- 3.Versporten A, Bielicki J, Drapier N, Sharland M, Goossens H. The Worldwide Antibiotic Resistance and Prescribing in European Children (ARPEC) point prevalence survey: developing hospital-quality indicators of antibiotic prescribing for children. J Antimicrob Chemother. 2016;71:1106–17.CrossRefPubMedGoogle Scholar
- 14.Food and Drug Administration. Professional drug information. 2017. https://www.drugs.com/pro/cefotaxime.html. Accessed 1 May 2017.
- 16.European Committee on Antimicrobial Susceptibility Testing. Antimicrobial wild type distributions of microorganisms. https://mic.eucast.org/Eucast2/SearchController/search.jsp?action=performSearch&BeginIndex=0&Micdif=mic&NumberIndex=50&Antib=44&Specium=-1. Accessed 1 Apr 2017.
- 21.van Zanten ARH, Oudijk M, Nohlmans-Paulssen MKE, van der Meer YG, Girbes ARJ, Polderman KH. Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy. Br J Clin Pharmacol. 2007;63:100–9.CrossRefPubMedGoogle Scholar
- 29.McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents. 2008;31:345–51.CrossRefPubMedGoogle Scholar
- 37.Roberts JA, Kirkpatrick CMJ, Roberts MS, Dalley AJ, Lipman J. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents. 2010;35:156–63.CrossRefPubMedGoogle Scholar
- 38.Abdul-Aziz MH, Lipman J, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, et al. Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. J Antimicrob Chemother. 2016;71:196–207.CrossRefPubMedGoogle Scholar
- 40.Abhilash B, Tripathi CD, Gogia AR, Meshram GG, Kumar M, Suraj B. Variability in plasma concentration of cefotaxime in critically ill patients in an Intensive Care Unit of India and its pharmacodynamic outcome: a nonrandomized, prospective, open-label, analytical study. J Pharmacol Pharmacother. 2016;7:15–21.CrossRefPubMedPubMedCentralGoogle Scholar